keyword
https://read.qxmd.com/read/38631003/overall-survival-with-adjuvant-pembrolizumab-in-renal-cell-carcinoma
#1
JOURNAL ARTICLE
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross-Goupil, Tian Zhang, John M Burke, Gurjyot Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stephane Oudard, Delphine Topart, Hans Hammers, Hiroshi Kitamura, David F McDermott, Adriano Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E Burgents, Rodolfo F Perini, Thomas Powles
BACKGROUND: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 1:1 ratio) participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks for up to 17 cycles (approximately 1 year) or until recurrence, the occurrence of unacceptable toxic effects, or withdrawal of consent...
April 18, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38630457/erenumab-for-treatment-of-persistent-erythema-and-flushing-in-rosacea-a-nonrandomized-controlled-trial
#2
JOURNAL ARTICLE
Nita K F Wienholtz, Casper E Christensen, Thien P Do, Lith E W Frifelt, Josefin Snellman, Cristina L Lopez-Lopez, Alexander Egeberg, Jacob P Thyssen, Messoud Ashina
IMPORTANCE: Treatment of erythema and flushing in rosacea is challenging. Calcitonin gene-related peptide (CGRP) has been associated with the pathogenesis of rosacea, raising the possibility that inhibition of the CGRP pathway might improve certain features of the disease. OBJECTIVE: To examine the effectiveness, tolerability, and safety of erenumab, an anti-CGRP-receptor monoclonal antibody, for the treatment of rosacea-associated erythema and flushing. DESIGN, SETTING, AND PARTICIPANTS: This single-center, open-label, single-group, nonrandomized controlled trial was conducted between June 9, 2020, and May 11, 2021...
April 17, 2024: JAMA Dermatology
https://read.qxmd.com/read/38629348/risks-of-serious-adverse-events-with-non-steroidal-anti-inflammatory-drugs-in-gastrointestinal-surgery-a-systematic-review-with-meta-analysis-and-trial-sequential-analysis
#3
REVIEW
Shaheer Bukhari, Morten F Leth, Christina C W Laursen, Mia E Larsen, Anders S Tornøe, Vibeke R Eriksen, Alfred E K Hovmand, Janus C Jakobsen, Mathias Maagaard, Ole Mathiesen
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly recommended for perioperative opioid-sparing multimodal analgesic treatments. Concerns regarding the potential for serious adverse events (SAEs) associated with perioperative NSAID treatment are especially relevant following gastrointestinal surgery. We assessed the risks of SAEs with perioperative NSAID treatment in patients undergoing gastrointestinal surgery. METHODS: We conducted a systematic review of randomised clinical trials assessing the harmful effects of NSAIDs versus placebo, usual care or no intervention in patients undergoing gastrointestinal surgery...
April 17, 2024: Acta Anaesthesiologica Scandinavica
https://read.qxmd.com/read/38629286/prognostic-impact-of-sinus-rhythm-in-atrial-fibrillation-patients-separating-rhythm-outcomes-from-randomized-strategy-findings-from-the-cabana-trial
#4
JOURNAL ARTICLE
T Jared Bunch, Jeanne E Poole, Adam P Silverstein, Kerry L Lee, Hussein R Al-Khalidi, Gerhard Hindricks, Alexander Romanov, Evgeny Pokushalov, Tristram D Bahnson, Melanie Daniels, Jonathan P Piccini, Daniel B Mark, Douglas L Packer
BACKGROUND: Clinically detected atrial fibrillation (AF) is associated with a significant increase in mortality and other adverse cardiovascular events. Since the advent of effective methods for AF rhythm control, investigators have attempted to determine how much these adverse prognostic AF effects could be mitigated by the restoration of sinus rhythm (SR) and whether the method used mattered. METHODS: The CABANA trial (Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) randomized 2204 AF patients to ablation versus drug therapy, of which 1240 patients were monitored in follow-up using the CABANA ECG rhythm monitoring system...
April 17, 2024: Circulation. Arrhythmia and Electrophysiology
https://read.qxmd.com/read/38628936/serious-adverse-events-with-cyanoacrylate-closure-of-varicose-veins-an-initial-report-from-a-large-scale-national-survey-in-japan
#5
JOURNAL ARTICLE
Michihisa Umetsu, Masayuki Hirokawa, Eri Fukaya, Eiichi Teshima, Hitoshi Kusagawa, Toshiya Nishibe, Hiroko Nemoto, Makoto Mo, Tomohiro Ogawa
Objective: Cyanoacrylate closure (CAC) is a minimally invasive technique for the treatment of varicose veins. A recent paper reported serious adverse events (AEs) associated with this use. This triggered an urgent survey to determine the incidence of AEs in Japan. Methods: The CAC-AE survey was sent to all 1,030 institutions authorized for CAC treatments. Cases performed between January 2020 and October 2023 were surveyed. Data on serious AEs and mortality were collected. Results: There were 623 surveys returned...
March 25, 2024: Annals of Vascular Diseases
https://read.qxmd.com/read/38628429/the-efficacy-of-neuromodulation-interventions-for-chemotherapy-induced-peripheral-neuropathy-a-systematic-review-and-meta-analysis
#6
REVIEW
Runbing Xu, Changhe Yu, Xinyu Zhang, Yipin Zhang, Mengfei Li, Bei Jia, Shiyan Yan, Miao Jiang
PURPOSE: To determine the efficacy and safety of a neuromodulation intervention regimen in the treatment of chemotherapy-induced peripheral neuropathy (CIPN). PATIENTS AND METHODS: Systematic searches were conducted in seven English databases. Randomized controlled trials of all neuromodulation interventions (both invasive and non-invasive) for the treatment of CIPN were selected. Group comparisons of differences between interventions and controls were also made...
2024: Journal of Pain Research
https://read.qxmd.com/read/38628292/bone-anchored-prostheses-for-transfemoral-amputation-a-systematic-review-of-outcomes-complications-patient-experiences-and-cost-effectiveness
#7
Mayank Rehani, Tania Stafinski, Jeff Round, C Allyson Jones, Jacqueline S Hebert
INTRODUCTION: Bone-anchored prostheses (BAP) are an advanced reconstructive surgical approach for individuals who had transfemoral amputation and are unable to use the conventional socket-suspension systems for their prostheses. Access to this technology has been limited in part due to the lag between the start of a new procedure and the availability of evidence that is required before making decisions about widespread provision. This systematic review presents as a single resource up-to-date information on aspects most relevant to decision makers, i...
2024: Front Rehabil Sci
https://read.qxmd.com/read/38627638/rimegepant-orally-disintegrating-tablet-75%C3%A2-mg-for-acute-treatment-of-migraine-in-adults-from-china-a-subgroup-analysis-of-a-double-blind-randomized-placebo-controlled-phase-3-clinical-trial
#8
RANDOMIZED CONTROLLED TRIAL
Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, Qian Zhao, Zhihong Lu
BACKGROUND: Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries. Previously, a large clinical trial assessed the efficacy and safety of rimegepant ODT 75 mg for the acute treatment of migraine in adults living in China or South Korea. A post hoc subgroup analysis of this trial was performed to evaluate the efficacy and safety of rimegepant for acute treatment of migraine in adults living in China...
April 16, 2024: Journal of Headache and Pain
https://read.qxmd.com/read/38627298/safety-of-masitinib-in-patients-with-neurodegenerative-diseases-a-meta-analysis-of-randomized-controlled-trials
#9
JOURNAL ARTICLE
Abdullah Ashraf Hamad, Basma Ehab Amer
OBJECTIVES: This meta-analysis aimed to examine the safety of masitinib in patients with neurodegenerative diseases. METHODS: We considered randomized controlled trials (RCTs) comparing different doses of masitinib versus placebo. We performed our analysis using the R (v.4.3.0) programming language and the incidence of adverse events was pooled using risk ratio (RR) and 95% confidence interval (CI). RESULTS: We included five RCTs, focusing on multiple sclerosis (MS), Alzheimer's disease (AD), and amyotrophic lateral sclerosis...
April 17, 2024: Neurological Sciences
https://read.qxmd.com/read/38626847/characterization-of-cardiovascular-serious-adverse-events-after-bypass-or-endovascular-revascularization-for-limb-threatening-ischemia-in-the-best-cli-trial
#10
JOURNAL ARTICLE
Jeffrey J Siracuse, Matthew T Menard, Kenneth Rosenfield, Michael S Conte, Richard Powell, Naomi Hamburg, Gheorghe Doros, Michael B Strong, Alik Farber
OBJECTIVES: Cardiovascular complications after revascularization to treat chronic limb threatening ischemia (CLTI) are a major concern that guides treatment. Our goal was to assess periprocedural cardiac and vascular serious adverse events (SAE) in the Best Endovascular versus Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial. METHODS: BEST-CLI was a prospective randomized trial comparing surgical (OPEN) and endovascular (ENDO) revascularization for patients with CLTI...
April 14, 2024: Journal of Vascular Surgery
https://read.qxmd.com/read/38625661/ruxolitinib-cream-1-5-a-review-in-non-segmental-vitiligo
#11
REVIEW
Connie Kang
Topical ruxolitinib 1.5% cream (Opzelura® ), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials, significantly more ruxolitinib cream recipients were able to achieve statistically significant and clinically meaningful facial and total body repigmentation, as well as reductions in vitiligo noticeability, compared with vehicle recipients...
April 16, 2024: Drugs
https://read.qxmd.com/read/38623449/case-report-a-rare-case-of-iodixanol-induced-anaphylactic-shock-in-cerebral-angiography
#12
Yang Zhao, Hua Wang, Zhengjun Wu, Yunxiang Zhu, Jingsong Wang
BACKGROUND: Adverse reactions induced by isoosmolar contrast medium (iodixanol) are mostly mild, with rashes and headaches being the most common. Although anaphylactic shock has been reported, no related incidents have been documented on cerebral angiography. OBJECTIVE: This article reports a serious case of anaphylactic shock possibly induced by iodixanol and provides an overview of the case report. CASE SUMMARY: A 65-year-old female with persistent headaches for nearly six months and CTA examination revealed multiple intracranial aneurysms...
2024: Journal of Asthma and Allergy
https://read.qxmd.com/read/38622851/use-of-approved-lu-177-radiopharmaceuticals-in-patients-with-end-stage-renal-disease-a-review-of-the-literature-and-proposed-treatment-algorithm
#13
JOURNAL ARTICLE
Nikolaos A Trikalinos, Hyun Kim, Anitha Vijayan, Maxwell Amurao, Vikas Prasad
Peptide receptor radionuclide therapy (PRRT) can be a very useful treatment for patients with neuroendocrine neoplasms and metastatic castration-resistant prostate cancer but it is routinely avoided in those with advanced kidney disease because it can adversely affect the renal function. Accordingly, no clear guidelines exist on the use of PRRT for patients on hemodialysis (HD). We performed a literature review to identify publications on HD patients who received PRRT with Lutetium-177 (Lu177 ) Dotatate and Y-90 and obtained information on Lu177 pharmacokinetics and early testing data from the manufacturer...
April 15, 2024: Journal of Neuroendocrinology
https://read.qxmd.com/read/38622456/detection-of-residual-peritoneal-metastases-following-cytoreductive-surgery-using-pegsitacianine-a-ph-sensitive-imaging-agent-final-results-from-a-phase-ii-study
#14
JOURNAL ARTICLE
Patrick Wagner, Edward A Levine, Alex C Kim, Perry Shen, Nicole D Fleming, Shannon N Westin, Laurel K Berry, Giorgos C Karakousis, Janos L Tanyi, Madeline T Olson, Brian Madajewski, Brian Ostrander, Kartik Krishnan, Charles M Balch, David L Bartlett
BACKGROUND: For patients with peritoneal carcinomatosis, extent of disease and completeness of cytoreductive surgery (CRS) are major prognostic factors for long-term survival. Assessment of these factors could be improved using imaging agents. Pegsitacianine is a pH-sensitive polymeric micelle conjugated to the fluorophore indocyanine green. The micelle disassembles in acidic microenvironments, such as tumors, resulting in localized fluorescence unmasking. We assessed the utility of pegsitacianine in detecting residual disease following CRS...
April 15, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38622211/empagliflozin-in-children-with-glycogen-storage-disease-associated-inflammatory-bowel-disease-a-prospective-single-arm-open-label-clinical-trial
#15
JOURNAL ARTICLE
Zhiling Li, Xiaoyan Zhang, Huan Chen, Hanshi Zeng, Jiaxing Wu, Ying Wang, Ni Ma, Jiaoli Lan, Yuxin Zhang, Huilin Niu, Lei Shang, Xun Jiang, Min Yang
Glycogen storage disease type Ib (GSD-Ib) is a rare inborn error of glycogen metabolism caused by mutations in SLC37A4. Patients with GSD-Ib are at high risk of developing inflammatory bowel disease (IBD). We evaluated the efficacy of empagliflozin, a renal sodium‒glucose cotransporter protein 2 (SGLT2) inhibitor, on colonic mucosal healing in patients with GSD-associated IBD. A prospective, single-arm, open-label clinical trial enrolled eight patients with GSD-associated IBD from Guangdong Provincial People's Hospital in China from July 1, 2022 through December 31, 2023...
April 15, 2024: Scientific Reports
https://read.qxmd.com/read/38621919/-clinical-comprehensive-evaluation-of-shexiang-tongxin-dropping-pills
#16
JOURNAL ARTICLE
Xia Tian, He Zhu, Wei Li, Sheng Han
Based on literature and questionnaire research, related evidence and related data on Shexiang Tongxin Dropping Pills were collected in terms of safety, effectiveness, economy, innovation, suitability, and accessibility. In addition, multi-criteria decision analysis(MCDA) model was used to comprehensively evaluate the clinical value of Shexiang Tongxin Dropping Pills. Quality control was carried out strictly based on evidence-based medicine evaluation. Shexiang Tongxin Dropping Pills were recommended for stable fatigue angina of coronary heart disease with Qi deficiency and blood stasis by guidelines and experts...
February 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/38621694/acceptability-and-feasibility-of-a-short-term-group-therapy-for-people-with-borderline-personality-disorder-symptoms
#17
JOURNAL ARTICLE
Dianna R Bartsch, Laura Cooke-O'Connor, Tracy J Connerty, Helen van Roekel, Paul Cammell
OBJECTIVE: This study evaluated the acceptance, feasibility and safety of a short-term group program for adults (18 years and older) and youth (16 to 18 years) with borderline personality disorder (BPD) symptoms. Termed Road Maps , the content and development were informed by common treatment factors identified from evidence-based therapies for BPD. METHOD: Two-hundred and eight people consented to participate in the research trial and completed baseline measures...
April 15, 2024: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://read.qxmd.com/read/38621405/safety-of-a-controlled-human-infection-model-of-tuberculosis-with-aerosolised-live-attenuated-mycobacterium-bovis-bcg-versus-intradermal-bcg-in-bcg-naive-adults-in-the-uk-a-dose-escalation-randomised-controlled-phase-1-trial
#18
JOURNAL ARTICLE
Iman Satti, Julia L Marshall, Stephanie A Harris, Rachel Wittenberg, Rachel Tanner, Raquel Lopez Ramon, Morven Wilkie, Fernando Ramos Lopez, Michael Riste, Daniel Wright, Marco Polo Peralta Alvarez, Nicola Williams, Hazel Morrison, Elena Stylianou, Pedro Folegatti, Daniel Jenkin, Samantha Vermaak, Linnea Rask, Ingrid Cabrera Puig, Rebecca Powell Doherty, Alison Lawrie, Paul Moss, Timothy Hinks, Henry Bettinson, Helen McShane
BACKGROUND: Mycobacterium tuberculosis is the main causative agent of tuberculosis. BCG, the only licensed vaccine, provides inadequate protection against pulmonary tuberculosis. Controlled human infection models are useful tools for vaccine development. We aimed to determine a safe dose of aerosol-inhaled live-attenuated Mycobacterium bovis BCG as a surrogate for M tuberculosis infection, then compare the safety and tolerability of infection models established using aerosol-inhaled and intradermally administered BCG...
April 12, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38621393/pharmacokinetics-and-safety-of-coformulated-bictegravir-emtricitabine-and-tenofovir-alafenamide-in-children-aged-2-years-and-older-with-virologically-suppressed-hiv-a-phase-2-3-open-label-single-arm-study
#19
JOURNAL ARTICLE
Carina A Rodriguez, Eva Natukunda, Renate Strehlau, Esme L Venter, Supattra Rungmaitree, Coleen K Cunningham, Umesh Lalloo, Pope Kosalaraksa, Elizabeth HellstrÖm, Afaaf Liberty, Eric J McGrath, Meenu Kaur, Rory Leisegang, Jason T Hindman, Vinicius A Vieira, Kathryn Kersey, Mark F Cotton, Natella Rakhmanina, Aditya H Gaur
BACKGROUND: Coformulated bictegravir, emtricitabine, and tenofovir alafenamide is a single-tablet regimen and was efficacious and well tolerated in children and adolescents with HIV (aged 6 years to <18 years) in a 48-week phase 2/3 trial. In this study, we report data from children aged at least 2 years and weighing 14 kg to less than 25 kg. METHODS: We conducted this open-label, multicentre, multicohort, single-arm study in South Africa, Thailand, Uganda, and the USA...
April 12, 2024: Lancet HIV
https://read.qxmd.com/read/38619757/resistance-is-not-futile-a-systematic-review-of-the-benefits-mechanisms-and-safety-of-resistance-training-in-people-with-heart-failure
#20
REVIEW
Bradley A Morris, Ronak Sinaei, Neil A Smart
Exercise offers many physical and health benefits to people with heart failure (CHF), but aerobic training (AT) predominates published literature. Resistance training (RT) provides additional and complementary health benefits to AT in people with CHF; we aimed to elucidate specific health benefits accrued, the mechanism of effect and safety of RT. We conducted a systematic search for RT randomised, controlled trials in people with CHF, up until August 30, 2023. RT offers several benefits including improved physical function (peak VO2 and 6MWD), quality of life, cardiac systolic and diastolic function, endothelial blood vessel function, muscle strength, anti-inflammatory muscle markers, appetite and serious event rates...
April 15, 2024: Heart Failure Reviews
keyword
keyword
159734
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.